Preclinical data shows efficacy of radio-therapeutic anti-HER2 agent
Affibody has shared the results of preclinical studies with its radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2-expressing metastatic disease.
The data were presented at the Annual Congress of the European Association of Nuclear Medicine by investigator Yongsheng Liu in the Professor Tolmachev group, Uppsala University.
The data demonstrate the strong therapeutic effect of HER2 targeted 177Lu, with significantly longer survival for the treatment group compared to trastuzumab standard of care treatment.
“These data suggest that our drug candidate could reach meaningful levels of drug in tumours of patients with metastatic disease,” said Fredrik Frejd, CSO, Affibody. “The drug is in late IND enabling development, and we anticipate early clinical data by mid next year.”
ABY-271 is a radiotherapeutic candidate aimed at tumour cells that express HER2, regardless of their position in the body. The project builds on previous clinical research insights from the development of tezatabep (ABY-025), showing that the candidate substance can bind to HER2 independently of the tumour origin.
ABY-271 emits therapeutic beta radiation, exerting irreversible damage to the cancer cells upon binding.
Affibody molecules are a novel drug class of small therapeutic proteins with characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments.
They have demonstrated clinical utilities both as tumour-targeting moieties through their small size and as efficacious disease blocking agents in autoimmune indications by utilising the inherent properties that allow multi-specific formats.
Diana Spencer, Senior Digital Content Editor, DDW
